In recent years, modern medicine reached tremendous progress via development of new technologies, new biological pharmaceuticals, personalized medicine and accompanying customized diagnostics. However, the need to face unsolved medical challenges is still enormous and even growing due to the fact of increased life expectancy and modern life style in civilized societies. Traditional therapies mainly focus on symptomatic treatment. In contrast, Regenerative Medicine/Therapies aims at strategies for a permanent restoration of affected organs or tissues. In addition, the patient’s own powers may activate endogenous regeneration which is stimulated via factors, cells and biomaterials.
About Berlin-Brandenburg Center for Regenerative Therapies (BCRT)
The research landscape of Berlin/Brandenburg has developed into one of the most important international clusters for Regenerative Medicine. A major contribution to this development has been the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), which was established 10 years ago. The BCRT is an interdisciplinary clinical translational center jointly operated by Charité Universitaetsmedizin Berlin and Helmholtz-Zentrum Geesthacht (with its site in Teltow). The BCRT’s focus lies on the concept of endogenous regeneration, which is realized by using cells, biomaterials, factors and the combination thereof, and addresses primarily diseases of the immune system, the musculoskeletal system and the cardiovascular system. First fruits of success with regard to the development and implementation of innovative therapies and products from BCRT are, e.g., virus-specific T-cell products for long-term protection against serious infections, which particularly affect patients with a weakened immune system. They are now evaluated in clinical studies on site. Following the concept of refined translation, i.e. iterative incorporation of (pre-)clinical research findings into product development, and the use of biomarkers, the BCRT is actively pushing further treatment concepts towards a clinical evaluation. This includes new cell-based approaches for heart disease and muscle injuries as well as new polymer-based devices like cardiovascular implants and systems for soft tissue regeneration or drug release. Such approaches may give rise to an enormous worldwide commercial potential, as the commercialization of Regenerative Medicine has just begun.
We cordially invite you to participate and discuss the latest trends and innovative technologies in Regenerative Medicine with stakeholders from academia and industry at the “RegMed Forum 2016 – 10 Years BCRT”. This scientific event is co-organized by the BCRT and the Cluster HealthCapital Berlin-Brandenburg, being the host of the RegMed Forum dedicated to Regenerative Medicine in the German capital region. The “RegMed Forum 2016 – 10 Years BCRT” provides the opportunity to network with important actors along the value chain and supports transferring innovations from basic research into clinics and industry. This year`s topic is endogenous regeneration with sessions on bone/muscle regeneration, cardiovascular diseases, immune cell therapies, biomaterials and regeneration, advanced disease models and technologies, as well as precision medicine. In addition to a comprehensive scientific program with presentations from local research groups, international guests from academia and industry, there will be plenty of opportunities for industry and new research groups to find an audience in presenting their profile and field of activities in the poster session, industry exhibition and partnering event.
We look forward to meeting you in Berlin!